SG10201500208SA - Npp1 fusion proteins - Google Patents
Npp1 fusion proteinsInfo
- Publication number
- SG10201500208SA SG10201500208SA SG10201500208SA SG10201500208SA SG10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA SG 10201500208S A SG10201500208S A SG 10201500208SA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion proteins
- npp1 fusion
- npp1
- proteins
- fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34006610P | 2010-03-12 | 2010-03-12 | |
| PCT/US2011/028233 WO2011113027A2 (en) | 2010-03-12 | 2011-03-11 | Npp1 fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500208SA true SG10201500208SA (en) | 2015-03-30 |
Family
ID=44564171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100341XA SG10202100341XA (en) | 2010-03-12 | 2011-09-15 | Npp1 fusion proteins |
| SG10201500208SA SG10201500208SA (en) | 2010-03-12 | 2011-09-15 | Npp1 fusion proteins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100341XA SG10202100341XA (en) | 2010-03-12 | 2011-09-15 | Npp1 fusion proteins |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US8846603B2 (en) |
| EP (1) | EP2545080B1 (en) |
| JP (3) | JP5735665B2 (en) |
| BR (1) | BR112013023010B1 (en) |
| CL (1) | CL2013002607A1 (en) |
| ES (2) | ES2628841T3 (en) |
| NZ (1) | NZ615070A (en) |
| SG (2) | SG10202100341XA (en) |
| TR (1) | TR201903573T4 (en) |
| WO (1) | WO2011113027A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2628841T3 (en) | 2010-03-12 | 2017-08-04 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
| ES2769836T3 (en) | 2010-09-09 | 2020-06-29 | Alexion Pharma Inc | Isolated Human Recombinant N-glycosylated Lysosomal Acid Lipase |
| EP2675472A4 (en) | 2011-02-15 | 2014-09-17 | Synageva Biopharma Corp | Methods for treating lysosomal acid lipase deficiency |
| AU2011362576B2 (en) * | 2011-03-11 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | NPP1 fusion proteins |
| JP6894664B2 (en) * | 2013-02-13 | 2021-06-30 | イエール ユニバーシティ | Compositions and methods for treating pathological calcification and ossification |
| EP2994759B1 (en) * | 2013-05-06 | 2018-09-12 | Bio-rad Laboratories, Inc. | Stabilization of labile analytes in reference materials |
| CN107109381A (en) * | 2014-12-19 | 2017-08-29 | 阿雷克森制药公司 | The method for treating tissue calcification |
| JP6995627B2 (en) | 2015-05-19 | 2022-02-04 | イエール ユニバーシティ | Compositions for treating pathological calcification conditions and methods of using them |
| JP2018537093A (en) * | 2015-11-20 | 2018-12-20 | イエール ユニバーシティ | Compositions for treating ectopic calcification disorders and methods of using same |
| WO2017218786A1 (en) * | 2016-06-16 | 2017-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| BR112019002355A2 (en) * | 2016-08-05 | 2019-07-16 | Univ Yale | compositions and methods for stroke prevention in pediatric patients with sickle cell anemia |
| EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | Enpp1 polypeptides and methods of using same |
| JP2023529892A (en) | 2020-06-09 | 2023-07-12 | イノザイム ファーマ インク． | Soluble ENPP1 or ENPP3 protein and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| WO1998035703A2 (en) | 1997-02-14 | 1998-08-20 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
| AU752946B2 (en) | 1997-10-16 | 2002-10-03 | Avigenics, Inc. | Vectors comprising a magnum-specific promoter for avian transgenesis |
| PT1032662E (en) | 1997-11-07 | 2006-07-31 | Trillium Therapeutics Inc | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION. |
| DE20121960U1 (en) * | 2000-04-06 | 2004-01-15 | Epigenomics Ag | New nucleic acid derived from chemically treated metastasis genes, useful for diagnosis of cancers by analysis of cytosine methylation, also for treatment |
| US20020108132A1 (en) | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
| WO2003072593A2 (en) | 2002-02-21 | 2003-09-04 | University Of Virginia Patent Foundation | Bone targeting peptides |
| US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
| EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US20090180989A1 (en) * | 2005-10-05 | 2009-07-16 | Synageva Biopharma Corp. | Compositions and methods for delivering nucleotide sequences to vertebrates |
| BR122019000505B1 (en) | 2007-05-11 | 2022-01-18 | Alexion Pharmaceuticals, Inc | BONE-TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF ITS USE |
| AR071885A1 (en) * | 2008-05-23 | 2010-07-21 | Wyeth Corp | PROTEINS OF UNION TO THE INTERLEUQUINE RECEIVER 21 |
| ES2628841T3 (en) | 2010-03-12 | 2017-08-04 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
-
2011
- 2011-03-11 ES ES11754231.6T patent/ES2628841T3/en active Active
- 2011-03-11 EP EP11754231.6A patent/EP2545080B1/en active Active
- 2011-03-11 WO PCT/US2011/028233 patent/WO2011113027A2/en active Application Filing
- 2011-03-11 US US13/583,973 patent/US8846603B2/en active Active
- 2011-09-15 NZ NZ615070A patent/NZ615070A/en not_active IP Right Cessation
- 2011-09-15 SG SG10202100341XA patent/SG10202100341XA/en unknown
- 2011-09-15 BR BR112013023010-0A patent/BR112013023010B1/en active IP Right Grant
- 2011-09-15 JP JP2013557704A patent/JP5735665B2/en active Active
- 2011-09-15 ES ES11861101T patent/ES2716526T3/en active Active
- 2011-09-15 SG SG10201500208SA patent/SG10201500208SA/en unknown
- 2011-09-15 US US14/004,294 patent/US20140154774A1/en not_active Abandoned
- 2011-09-15 TR TR2019/03573T patent/TR201903573T4/en unknown
-
2013
- 2013-09-10 CL CL2013002607A patent/CL2013002607A1/en unknown
-
2014
- 2014-08-01 US US14/449,364 patent/US9540621B2/en active Active
- 2014-10-06 US US14/507,124 patent/US20150024460A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084216A patent/JP6096826B2/en active Active
-
2017
- 2017-01-27 US US15/417,590 patent/US20170145393A1/en not_active Abandoned
- 2017-02-16 JP JP2017026961A patent/JP6484905B2/en active Active
-
2020
- 2020-11-25 US US17/105,245 patent/US20210301268A1/en not_active Abandoned
-
2022
- 2022-08-11 US US17/819,065 patent/US20230129977A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013023010A2 (en) | 2018-07-03 |
| US20140377859A1 (en) | 2014-12-25 |
| US20170145393A1 (en) | 2017-05-25 |
| US20150024460A1 (en) | 2015-01-22 |
| US20130273021A1 (en) | 2013-10-17 |
| JP2014509851A (en) | 2014-04-24 |
| US20210301268A1 (en) | 2021-09-30 |
| WO2011113027A2 (en) | 2011-09-15 |
| WO2011113027A3 (en) | 2012-03-01 |
| JP6096826B2 (en) | 2017-03-15 |
| EP2545080B1 (en) | 2017-05-10 |
| JP2017137318A (en) | 2017-08-10 |
| JP5735665B2 (en) | 2015-06-17 |
| EP2545080A2 (en) | 2013-01-16 |
| ES2628841T3 (en) | 2017-08-04 |
| US8846603B2 (en) | 2014-09-30 |
| ES2716526T3 (en) | 2019-06-13 |
| US9540621B2 (en) | 2017-01-10 |
| JP6484905B2 (en) | 2019-03-20 |
| SG10202100341XA (en) | 2021-02-25 |
| NZ615070A (en) | 2015-10-30 |
| CL2013002607A1 (en) | 2014-03-28 |
| US20230129977A1 (en) | 2023-04-27 |
| EP2545080A4 (en) | 2013-09-11 |
| JP2015164427A (en) | 2015-09-17 |
| TR201903573T4 (en) | 2019-04-22 |
| US20140154774A1 (en) | 2014-06-05 |
| BR112013023010B1 (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150241T1 (en) | Anticancer fusion protein | |
| HK1192587A1 (en) | Therapeutic fusion proteins | |
| EP2616896A4 (en) | Sensor fusion | |
| EP2638072A4 (en) | Fusion proteins for hiv therapy | |
| EP2634188A4 (en) | Fused aminodihydropyrimidine derivative | |
| PL3321287T3 (en) | Fusion proteins & combination vaccines | |
| SG10202100341XA (en) | Npp1 fusion proteins | |
| HK1186192A1 (en) | Anticancer fusion protein | |
| ZA201300066B (en) | Fusion protein having factor vii activity | |
| IL226481A0 (en) | Fusion enzymes | |
| EP2683742A4 (en) | Npp1 fusion proteins | |
| EP2698386A4 (en) | Fusion protein | |
| HK1187369A1 (en) | Fusion protein for secretory protein expression | |
| EP2657337A4 (en) | Fusion protein | |
| GB201016494D0 (en) | Polypeptide | |
| EP2521787A4 (en) | Enhanced protein expression | |
| ZA201207425B (en) | Fusion protein | |
| GB201007834D0 (en) | Growth promoting fusion proteins | |
| GB201007955D0 (en) | Somatosatin fusion proteins | |
| GB201114701D0 (en) | Fusion proteins | |
| GB201107189D0 (en) | Fusion proteins | |
| GB201010202D0 (en) | Fusion polypeptides | |
| GB201007550D0 (en) | Modified receptor fusion proteins | |
| GB201004150D0 (en) | Modified receptor fusion proteins | |
| PL393146A1 (en) | Anticancer fusion protein |